PL376525A1 - Sposób modyfikacji pokroju kryształów substancji leczniczej - Google Patents

Sposób modyfikacji pokroju kryształów substancji leczniczej

Info

Publication number
PL376525A1
PL376525A1 PL376525A PL37652504A PL376525A1 PL 376525 A1 PL376525 A1 PL 376525A1 PL 376525 A PL376525 A PL 376525A PL 37652504 A PL37652504 A PL 37652504A PL 376525 A1 PL376525 A1 PL 376525A1
Authority
PL
Poland
Prior art keywords
crystal formation
drug crystal
modifying drug
modifying
formation
Prior art date
Application number
PL376525A
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL376525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL376525A1 publication Critical patent/PL376525A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL376525A 2003-01-20 2004-01-19 Sposób modyfikacji pokroju kryształów substancji leczniczej PL376525A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds

Publications (1)

Publication Number Publication Date
PL376525A1 true PL376525A1 (pl) 2006-01-09

Family

ID=9951448

Family Applications (2)

Application Number Title Priority Date Filing Date
PL376525A PL376525A1 (pl) 2003-01-20 2004-01-19 Sposób modyfikacji pokroju kryształów substancji leczniczej
PL393385A PL213192B1 (pl) 2003-01-20 2004-01-19 Sposób modyfikacji pokroju krysztalów substancji leczniczej, krysztaly mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL393385A PL213192B1 (pl) 2003-01-20 2004-01-19 Sposób modyfikacji pokroju krysztalów substancji leczniczej, krysztaly mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna

Country Status (32)

Country Link
US (3) US20060122265A1 (pl)
EP (2) EP2308471A1 (pl)
JP (1) JP4549976B2 (pl)
KR (5) KR101129105B1 (pl)
CN (2) CN100595199C (pl)
AR (2) AR043343A1 (pl)
AT (1) ATE546132T1 (pl)
AU (1) AU2004206731B2 (pl)
BR (1) BRPI0406827A (pl)
CA (2) CA2706900A1 (pl)
CL (1) CL2004000073A1 (pl)
CO (1) CO5580738A2 (pl)
CY (1) CY1112772T1 (pl)
DK (1) DK1592401T3 (pl)
EC (1) ECSP055918A (pl)
ES (1) ES2382035T3 (pl)
GB (1) GB0301259D0 (pl)
HK (1) HK1084874A1 (pl)
IL (1) IL169484A (pl)
MX (1) MXPA05007691A (pl)
MY (1) MY148297A (pl)
NO (1) NO20053846L (pl)
NZ (1) NZ541073A (pl)
PE (2) PE20040826A1 (pl)
PL (2) PL376525A1 (pl)
PT (1) PT1592401E (pl)
RU (1) RU2388757C2 (pl)
SG (1) SG155046A1 (pl)
SI (1) SI1592401T1 (pl)
TW (1) TWI325785B (pl)
WO (1) WO2004064806A2 (pl)
ZA (1) ZA200504442B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
CA2555454C (en) 2004-04-27 2009-12-15 Sandor Molnar Mycophenolate mofetil impurity
CN101014584A (zh) 2004-07-20 2007-08-08 特瓦药厂私人有限公司 结晶霉酚酸钠的制备方法
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US8314122B2 (en) * 2008-10-09 2012-11-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EA036793B1 (ru) * 2015-12-21 2020-12-22 Янссен Фармацевтика Нв Способ кристаллизации для получения кристаллов гемигидрата канаглифлозина
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
CZ292423B6 (cs) 1993-09-15 2003-09-17 Syntex (U.S.A.) Inc. Krystalický, bezvodý mykofenolát mofetilu a intravenózní prostředek, ve kterém je obsažen
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2706900A1 (en) 2004-08-05
AU2004206731A8 (en) 2004-08-05
GB0301259D0 (en) 2003-02-19
DK1592401T3 (da) 2012-05-21
PT1592401E (pt) 2012-05-10
US20060122265A1 (en) 2006-06-08
ECSP055918A (es) 2005-11-22
US20090209639A1 (en) 2009-08-20
ATE546132T1 (de) 2012-03-15
CL2004000073A1 (es) 2005-01-14
KR20090115898A (ko) 2009-11-09
TW200505505A (en) 2005-02-16
AR103711A2 (es) 2017-05-31
CA2509796C (en) 2010-09-14
KR20090115821A (ko) 2009-11-06
TWI325785B (en) 2010-06-11
MXPA05007691A (es) 2005-09-30
PL213192B1 (pl) 2013-01-31
RU2388757C2 (ru) 2010-05-10
PE20040826A1 (es) 2004-12-23
US8124795B2 (en) 2012-02-28
CY1112772T1 (el) 2016-02-10
SI1592401T1 (sl) 2012-05-31
SG155046A1 (en) 2009-09-30
EP1592401B1 (en) 2012-02-22
IL169484A (en) 2016-03-31
EP2308471A1 (en) 2011-04-13
BRPI0406827A (pt) 2005-12-27
CO5580738A2 (es) 2005-11-30
EP1592401A2 (en) 2005-11-09
WO2004064806A2 (en) 2004-08-05
KR100855149B1 (ko) 2008-08-28
CN100595199C (zh) 2010-03-24
AR043343A1 (es) 2005-07-27
KR20070087181A (ko) 2007-08-27
KR20050096940A (ko) 2005-10-06
KR101129105B1 (ko) 2012-04-12
CA2509796A1 (en) 2004-08-05
ES2382035T3 (es) 2012-06-04
US8008511B2 (en) 2011-08-30
AU2004206731A1 (en) 2004-08-05
RU2005126328A (ru) 2006-07-27
IL169484A0 (en) 2007-07-04
HK1084874A1 (en) 2006-08-11
KR20100120321A (ko) 2010-11-15
ZA200504442B (en) 2006-02-22
AU2004206731B2 (en) 2008-03-20
PL393385A1 (pl) 2011-03-14
JP2006515016A (ja) 2006-05-18
WO2004064806A3 (en) 2004-10-28
CN1738605A (zh) 2006-02-22
PE20110276A1 (es) 2011-05-27
CN101333201A (zh) 2008-12-31
US20110288313A1 (en) 2011-11-24
NZ541073A (en) 2008-12-24
JP4549976B2 (ja) 2010-09-22
MY148297A (en) 2013-03-29
NO20053846L (no) 2005-08-16

Similar Documents

Publication Publication Date Title
IL169484A0 (en) Process for modifying drug crystal formation
EP1813677A4 (en) PROCESS FOR MAKING BASIC SUBSTANCE
IL178233A0 (en) Process for producing 5-hydroxy-4-thiomethylpyrazole derivatives
HK1095817A1 (en) Method for the production of amino crotonyl compounds
HRP20150163T1 (en) Process for the preparation of n-substituted 2-cyanopyrrolidines
EP1813700A4 (en) APPARATUS FOR THE PRODUCTION OF CRYSTALS
EP1592052A4 (en) PROCESS FOR DISPLAY PRODUCTION
SG137677A1 (en) Improved process for preparing polyalkenylsuccinimides
AU2003254835A1 (en) Process for producing proanthocyanin-rich material
PL378077A1 (pl) Sposób wytwarzania para-ksylenu
EP1650332A4 (en) PROCESS FOR CRYSTAL PRODUCTION AND CRYSTAL
EP1614774A4 (en) PROCESS FOR PRODUCING A SINGLE CRYSTAL
EP1624094A4 (en) PROCESS FOR PRODUCING MONOCRYSTAL AND MONOCRYSTAL OBTAINED BY THIS PROCESS
EP1614671A4 (en) PROCESS FOR PRODUCING ISOPRENE
EP1679392A4 (en) PROCESS FOR PRODUCING MONOCRYSTAL
EP1604957A4 (en) PROCESS FOR PRODUCING GLASS MATERIAL
EP1612213A4 (en) PROCESS FOR PREPARING 2-DESOXY-2-FLUORURIDINE
SI1551414T1 (sl) Postopek za pripravo kristalne oblike I olanzapina
EP1693397A4 (en) PROCESS FOR PRODUCING POLYHYDROXYALCANOATE CRYSTAL
EP1754738A4 (en) PROCESS FOR PREPARING POLYPYRIDINIUM
EP1698703A4 (en) PROCESS FOR DIPEPTIDE PRODUCTION
EP1683776A4 (en) METHOD FOR PRODUCING A RADIOACTIVE, FLUORMARKED COMPOUND
AU2003289070A8 (en) Phospholipid derivatives and process for the production there
AU2003236336A1 (en) Process for producing tablet
PL1698619T3 (pl) Sposób wytwarzania pochodnej 2-halogenobenzamidu

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)